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Abstract
In contrast to adult mutant gastrointestinal stromal tumors [GISTs], pediatric/wild-type GISTs remain poorly understood
overall, given their lack of oncogenic activating tyrosine kinase mutations. These GISTs, with a predilection for gastric origin
in female patients, show limited response to therapy with tyrosine kinase inhibitors and generally pursue a more indolent
course, but still may prove fatal. Defective cellular respiration appears to underpin tumor development in these wild-type
cases, which as a group lack expression of succinate dehydrogenase [SDH] B, a surrogate marker for respiratory chain
metabolism. Yet, only a small subset of the wild-type tumors show mutations in the genes coding for the SDH subunits
[SDHx]. To explore additional pathogenetic mechanisms in these wild-type GISTs, we elected to investigate post-
transcriptional regulation of these tumors by conducting microRNA (miRNA) profiling of a mixed cohort of 73 cases
including 18 gastric pediatric wild-type, 25 (20 gastric, 4 small bowel and 1 retroperitoneal) adult wild-type GISTs and 30
gastric adult mutant GISTs. By this approach we have identified distinct signatures for GIST subtypes which correlate tightly
with clinico-pathological parameters. A cluster of miRNAs on 14q32 show strikingly different expression patterns amongst
GISTs, a finding which appears to be explained at least in part by differential allelic methylation of this imprinted region.
Small bowel and retroperitoneal wild-type GISTs segregate with adult mutant GISTs and express SDHB, while adult wild-
type gastric GISTs are dispersed amongst adult mutant and pediatric wild-type cases, clustering in this situation on the basis
of SDHB expression. Interestingly, global methylation analysis has recently similarly demonstrated that these wild-type,
SDHB-immunonegative tumors show a distinct pattern compared with KIT and PDGFRA mutant tumors, which as a rule do
express SDHB. All cases with Carney triad within our cohort cluster together tightly.
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Introduction
Gastrointestinal stromal tumor (GIST) is the commonest
sarcoma of the gastrointestinal tract, typically presenting clinically
in patients aged 55–65 years [1]. Classically, GISTs are
characterised by activating mutations in the genes encoding the
type III tyrosine kinase receptors, KIT [2] occurring in ,80–85%,
or Platelet-Derived Growth Factor Receptor, alpha PDGFRA [3], in 5–8%
of GISTs [1]. These mutually exclusive mutations cause ligand-
independent auto-phosphorylation of the receptor, activating
crucial growth and survival signalling cascades. Rare GISTs,
lacking KIT and PDGFRA mutations, have been found to contain a
common BRAF exon 15 activating mutation resulting in a V600E
substitution [4]. The 10–15% of GISTs with no detectable KIT,
PDGFRA or BRAF mutations have been termed ‘wild-type’ (WT)
GISTs. WT GISTs are generally KIT immunopositive [5] and
have similar downstream signalling to mutant tumors, despite the
lack of activating mutations [5]. The majority of pediatric GISTs
are WT, typically presenting as slow-growing gastric tumors in
prepubescent girls.
Additional key differences between adult and pediatric GIST
include large-scale genomic losses of chromosomes 14q, 22q, 1p
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and 9p with disease progression in adult tumors [6], changes
which are mostly absent in pediatric GISTs or in tumors
associated with Carney Triad and Carney-Stratakis syndromes
[7]. Differences in mRNA expression profiles between adult and
pediatric GISTs have also been reported [8,9]. WT GIST may be
associated with a number of syndromes including Neurofibroma-
tosis type-1 (NF-1), Carney triad and Carney-Stratakis syndrome
(or Carney dyad). Carney triad describes the non-heritable
association of GIST with extra-adrenal paragangliomas and
pulmonary chondromas [10], while Carney-Stratakis syndrome
is inherited as an autosomal dominant trait and describes the
association of paraganglioma and GIST [11]. The dyad is caused
by germline mutations in the succinate dehydrogenase (SDH) subunits
B, C or D (SDHx) genes [12]. Absent SDHB expression by
immunohistochemistry has been reported in GISTs of Carney
triad [13] and indeed WT GIST more broadly [14], however
germline mutations of SDH B, C or D were identified in only 12%
of such cases without a family history of paraganglioma [14]. Very
recently, it has emerged that mutations of SDHA also occur in
adult WT GIST and indeed ,50% of adult WT GISTs contain
SDHx mutations with ,70% of these in SDHA [15,16]. By
contrast, SDHB is strongly expressed in KIT- and PDGFRA-
mutant GISTs [13,14].
Given that the oncogenic changes identified at a genomic level
in mutant GISTs are not seen in the WT setting, we hypothesized
that paediatric and adult WT GISTs are driven in significant part
at least by epigenetic and/or post-transcriptional dysregulation.
With that in mind, this study was conducted to profile miRNA
expression in pediatric and adult WT GIST compared to adult
mutant GIST.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the Medical Research
Ethics Committee, Our Lady’s Children’s Hospital, Crumlin,
Dublin 12, Ireland for the use of anonymised, pre-existing
(archival) diagnostic material from GIST specimens collected
from various European and American sources. The participants all
gave written informed consent up-front at diagnosis for inclusion
in biological studies of their respective country’s cancer group as a
global consent.
Cases for Study
Samples were collected from European and US collaborators
(see acknowledgements). Age categorisation was: ,20 years as
pediatric and ./= 20years as adult. Previously genotyped adult
mutant GISTs (cases 1–27) were obtained from the archives of
MD-R. Additional adult mutant, pediatric and adult WT cases
were collected mainly from the NIH pediatric and wild-type GIST
clinic, with additional cases accrued from European sources.
These cases were mainly gastric, given that pediatric GIST
classically arises in the stomach, but also included four small bowel
and one retroperitoneal WT case, as this material became
available. These cases were all genotyped in the laboratory of
MO’S such that the final cohort comprised 30 adult mutant [1.5
male: 1 female; all gastric], 25 adult WT (1 male: 4 female; 20
gastric : 4 small bowel : 1 retroperitoneal) and 18 pediatric WT (1
male: 2 female; all gastric) cases.
DNA and RNA Extraction
Unstained sections were cut from paraffin blocks at 10 mm (5
per sample) and macro-dissected for tumor tissue only. DNA and
RNA extraction was performed using the RecoverAllTM Total
Nucleic Acid Isolation Kit for FFPE (AmbionH, Austin, TX, USA),
which is known to preserve miRNAs, as per manufacturer’s
instructions and quantified using the Nanodrop ND 1000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
Mutational Analysis
Tumor DNA was PCR-amplified for KIT exons 9, 11, 13, 17
and PDGFRA exons 12, 14, and 18 using previously published
primers for KIT exons 9, 11 and 13 [17] and newly-designed
primers for all other exons tested (Table S1). The PCR products
were examined by High Resolution Melt Curve Analysis, with LC
Green (Idaho Technology, Salt Lake City UT, USA) and analysed
using the Roche LightCycler (Roche, Burgess Hill, West Sussex,
UK). Samples with aberrant melt curves were subjected to Sanger
sequencing (LGC Genomics GmbH, Berlin, Germany). PCR
amplification and sequencing of BRAF exon 15 was conducted for
adult WT gastric, small bowel and retroperitoneal GISTs using
forward primer 59TGCTTGCTCTGATAGGAAAATG and
reverse primer 59AGCATCTCAGGGCCAAAAAT with an
annealing temperature of 59uC.
MicroRNA Profiling and Data Pre-processing
MiRNA profiling was performed using TaqManH Low Density
Arrays (Applied Biosystems, Foster City, CA, USA). TaqManH
Low Density Arrays allow the profiling and accurate quantitation
of 667 miRNAs in a set of two 384-well cards; pool A and pool B,
with the cards containing MammU6, RNU24, 43, 44, 48 and 6B
as internal controls. Reverse transcription was performed using the
TaqManH MicroRNA Reverse Transcription Kit (Applied Bio-
systems, Foster City, CA, USA) and MegaPlexTM RT primers
(Applied Biosystems, Foster City, CA, USA) pool A and pool B.
Products from the reverse transcription were pre-amplified using
TaqManH PreAmp MasterMix and PreAmp primers (pool A and
pool B) (Applied Biosystems, Foster City, CA, USA). The array
cards were loaded with the preamplified sample and run on the
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA). Ct values over 35 were considered noise and were
disregarded. MiRNAs expressed in less than 20% of samples were
excluded from analysis. Mean normalization was carried out by
subtracting the mean sample Ct from individual Ct values.
Normalized relative expression of miRNAs was calculated with
reference to Ct max using: Normalized relative expression =
2(Ctmax2Ct).
Technical Validation
Three miRNAs, miR-455-5p, miR-488 and miR-124 were used
to validate the arrays. Mature miRNA expression levels were
evaluated using individual TaqManH miRNA assay (Applied
Biosystems, Foster City, CA, USA) according to the manufactur-
er’s protocol.
Data Analysis and Visualization
Cluster Analysis, heatmap generation and boxplots were
performed using hclust, heatmap.plus and graphics packages from R
statistical programming language v2.8.1. Hierarchical clustering
was performed using Spearman’s rank correlation and Ward’s
linkage. Heatmap colouring was based on rank of sample value
across each miRNA. Statistically significant (p,0.05) changes in
miRNA expression levels over various sample classes were
calculated using Wilcoxon’s rank-sum test and corrected for
multiple comparisons using Bonferroni method. Next, the data
were interrogated for miRNAs which showed statistically signif-
icant (p,0.05) differential expression between the classes: 1) adult
GIST Pathogenesis and microRNA
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mutant vs. pediatric GIST, 2) adult WT vs. pediatric WT, 3) adult
[all] vs. pediatric GIST, 4) adult WT vs. adult mutant GIST, 5) all
WT vs. all mutant GIST, 6) cases in cluster B2a vs. B2b (which
contains all Carney triad cases, n = 4 known at the time of writing)
from the heatmap, and for cases where relevant data were
available additional analysis included : 7) SDHB-immunopositive
vs. SDHB-immunonegative, 8) 14q loss vs. no loss, and for adult
samples alone: 9) high vs. low risk, 10) outcome: died of disease or
alive with disease vs. no evidence of disease. As miRNAs function
by either degrading target mRNAs or blocking their translation,
we were interested in seeking evidence of such interactions. To this
end we integrated mRNA expression data and predicted target
data (TargetScan [18–20]) to establish which sets of miRNA and
mRNA were - 1) diametrically expressed across GIST classes and
2) had an over-representation of predicted binding interactions.
miRNA : mRNA interactions were examined using our data for
differentially expressed miRNAs and pre-existing mRNA expres-
sion data [based on data from differentially expressed genes
previously published [5,9,21–28] and indeed full raw, unpublished
gene expression data [5]. This analysis involved assessment of the
number of predicted interactions (listed in TargetScan [18–20])
compared to those expected by chance usingMirMatcher, a custom-
built software application, implemented in Java. The comparisons
that were possible included differential mRNA expression between
classes: 1) Genes higher in pediatric compared to adult mutant –
miRNAs lower in pediatric compared to adult mutant, 2) Genes
lower in pediatric compared to adult – miRNAs higher in
pediatric compared to adult, 3) Genes higher in mutant compared
to WT – miRNAs lower in mutant compared to WT, 4) Genes
higher in WT compared to mutant – miRNAs lower in WT
compared to mutant, 5) Genes higher in pediatric compared to
adult WT – miRNAs lower in pediatric compared to adult WT
and 6) Genes higher in pediatric compared to adult mutant –
miRNAs lower in pediatric compared to adult mutant and
corresponding diametrically expressed miRNAs for the published
gene expression data; and classes WT vs. mutant for the
Table 1. Adult Mutant GIST case demographics.
Case Sex Age Location Genotype Mutation 14q32 Status SDHB IHC Follow-up Risk Histology
1 F 58 Stomach KIT ex 11 Y553_W557del Loss NA DOD H S
2 F 37 Stomach PDGFRA ex 18 D842V Loss NA WD L S
3 M 55 Stomach PDGFRA ex 14 N659K Loss NA WD L E
4 F 73 Stomach PDGFRA ex 18 D842V Loss NA WD L E
5 F 54 Stomach KIT ex 11 M552_W557del Loss NA WD I S&E
6 M 44 Stomach KIT ex 11 W557R Loss NA WD I S&E
7 F 78 Stomach KIT ex 11 P551_E561delinsLQ Diploid NA AWD H S
8 F 65 Stomach KIT ex 11 W557_V560delinsF Loss NA AWD H E
9 M 85 Stomach KIT ex 11 V559A Loss NA WD L S&E
10 M 62 Stomach PDGFRA ex 18 D842V Loss NA WD H E
11 M 44 Stomach PDGFRA ex 18 D842V Loss NA WD I S
12 M 70 Stomach KIT ex 11 W557_K558del Loss NA AWD H E
13 M 77 Stomach KIT ex 11 V559D Loss NA WD L E&S
14 F 27 Stomach KIT ex 11 556_573del Loss NA AWD I S
15 M 71 Stomach KIT ex 11 V560_G565del Loss NA AWD H S
16 M 72 Stomach PDGFRA ex 18 D842_M844del Loss NA WD I E
17 M 72 Stomach KIT ex 11 K558_V559delinsN Loss NA AWD H S
18 M 62 Stomach KIT ex 11 V554D Loss NA WD I S
19 M 67 Stomach KIT ex 11 W557_K558del Diploid NA DOD H S
20 M 69 Stomach PDGFRA ex 18 D842_I843del Loss NA WD I S
21 M 74 Stomach KIT ex 11 V560D Loss NA DOD H E
22 F 48 Stomach KIT ex 11 K550_V555del Loss NA WD H S
23 M 49 Stomach PDGFRA ex 18 D842V Trisomy NA WD H E
24 M 68 Stomach PDGFRA ex 12 V561D Loss NA WD I E&S
25 M 50 Stomach PDGFRA ex 18 D842V Loss NA WD L E
26 F 71 Stomach KIT ex 11 W557_K558del Loss NA AWD H E
27 F 46 Stomach PDGFRA ex 18 D842V Diploid NA WD I E
50 F 58 Stomach KIT ex 9 S476I NA positive NA NA E&S
51 F 22 Stomach KIT ex 11 Y553_W557del NA positive NA NA E
52 M 58 Stomach BRAF ex 15 V600E Diploid positive NA NA E&S
NA – Not Available, DOD – Died of Disease, WD – Without Disease, AWD - Alive with Disease, WT – Wild-Type, S – Spindle, E - Epithelioid.
Patient demographics including age, sex, syndromic association and outcome, as well as data pertaining to tumors including anatomic location, histological type, KIT/
PDGFRA/BRAF mutational status, 14q status, risk and SDH immunoreactivity where available.
doi:10.1371/journal.pone.0064102.t001
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unpublished full raw mRNA expression data to which we had
access.
Fluorescence In-Situ Hybridisation [FISH]
FISH analysis for 14q32 loss in adult mutant samples and
selected adult WT and pediatric samples, was performed on 4 mm
formalin-fixed paraffin-embedded tissue sections as previously
described [29]. Ploidy was investigated using double colour locus
specific identifier IGH/CCND1 (Applied Biosystems, Foster City,
CA, USA), which contains differently labelled probes for IGH/
14q32 and CCND1/11q12 genes. Detection was by previously
described methods [29].
Methylation Specific PCR for 14q32
Bisulfite conversion of 1 mg of genomic DNA (where
available) was performed with the EpiTect Bisulfite Kit (Qiagen
GmbH, Crawley, West Sussex, UK) following the protocol for
formalin-fixed paraffin-embedded samples. Methylation specific
PCR reactions were performed using ‘maternal’ and ‘paternal’
primers for the differentially methylated 59 region of the MEG3
promoter as described [30]. Briefly, 50 ng of bisulfite converted
DNA was amplified in a 25 mL volume, with 2.5units
HotStarTaq DNA Polymerase, 1X Buffer, 200 mM each dNTP
(Qiagen GmbH, Crawley, West Sussex, UK), 0.4 mM each
methylated primer and 0.8 mM each unmethylated primer.
Cycling conditions were 95uC 15 mins, 35 cycles of 94uC 30 s,
58uC 1 min, 72uC 1 min and final extension 72uC 10 mins.
PCR products were run on 2.5% agarose gels and post-stained
with GelStar Nucleic Acid Stain (Lonza, Muenchensteiner-
strasse, Basel, Switzerland). Gels were visualised using a
transilluminator.
Succinate Dehydrogenase B Immunohistochemistry
Where tissue sections from tumors were available, SDHB
immunohistochemistry was evaluated using a mouse monoclonal
antibody 21A11AE7 (Abcam, Cambridge, MA, USA). The
primary antibody dilution was 1:1000, and immunostaining in a
Leica Bond-Max automated immunostainer (Leica Biosystems,
Nussloch, Germany) included a step of heat-induced epitope
retrieval by a high-pH buffer for 25 min. Primary antibody was
incubated for 30 min, and the detection system for 15 min.
Diaminobenzidine was used as the chromogen.
Cell Culture and Transfection
No wild-type GIST cell lines are currently available. The GIST
T1 cell line was established by Taguchi [31] from a metastatic
GIST of the stomach and harbours a KIT exon 11 mutation.
GIST T1 cells were a generous gift from Dr. Jonathan Fletcher
(Dana-Farber Cancer Institute, Boston, MA, USA) and were
cultured in Iscove’s Modified Dulbecco’s Medium (IMDM)
Table 2. Adult WT case demographics.
Case Sex Age Location Genotype Mutation 14q32 Status SDHB IHC Follow-up Risk Histology
28 F 24 Stomach WT WT NA NA NA NA E
29 F 22 Stomach WT WT NA NA NA NA E
30 F 20 Stomach WT WT NA NA NA NA E
32 F 22 Stomach WT WT NA NA NA NA E
35 F 23 Stomach WT WT NA negative NA NA E
36 F 21 Stomach WT WT Diploid negative NA NA E
38 F 25 Stomach WT WT Diploid negative NA NA E
46 M 22 Stomach WT WT NA negative NA NA E
48 M 20 Stomach WT WT NA negative NA NA E
49 F 46 [26] Stomach WT WT NA negative NA NA NA
53 F 20 Jejunum WT WT Diploid positive NA NA E&S
54 F 78 Stomach WT WT NA NA NA NA E
55 F 50 Stomach WT WT NA NA NA NA E
56 M 42 Stomach WT WT NA NA NA NA S
60 F 33 Stomach WT WT NA positive NA NA S
63 F 30 Jejunum WT WT Diploid positive NA NA S
64 F 40 Stomach WT WT NA negative NA NA E
65 F* 28 Stomach WT WT NA negative NA NA E
66 F 54 Ileum WT WT Diploid positive NA NA S
68 F 55 Stomach WT WT NA negative NA NA E
69 F 49 Stomach WT WT NA negative NA NA E
70 F 31 Stomach WT WT NA negative NA NA E
71 M 45 Ileum WT WT Trisomy positive NA NA E
72 F 46 Stomach WT WT NA positive NA NA S
73 M 37 Retroperitoneum WT WT Diploid positive NA NA S
Patient demographics including age, sex, syndromic association and outcome, as well as data pertaining to tumors including anatomic location, histological type, KIT/
PDGFRA/BRAF mutational status, 14q status, risk and SDH immunoreactivity where available.
doi:10.1371/journal.pone.0064102.t002
GIST Pathogenesis and microRNA
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e64102
supplemented with 1% penicillin/streptomycin and 10% fetal
bovine serum (FBS). Cells were maintained at 37uC in a
humidified incubator with 5% CO2.
miRNA precursors and a scrambled oligonucleotide control
(AmbionH, Austin, TX, USA) were transiently transfected into
cells using siPORT NeoFX (AmbionH, Austin, TX, USA) as per
manufacturer’s instructions.
Cell Proliferation Assay
Cell proliferation was assessed using the CellTitre 96 AQueous
Non-Radioactive Proliferation Assay (MTS) (Promega Corpora-
tion, Madison, WI, USA). Cells were transfected with miRNA
precursors (miR-34c-5p, miR-185 and miR-190), scrambled
oligonucleotide control (SCR) or siKinesin (KIN), a positive
control for decreased cell proliferation, and seeded into 96 well
Table 3. Pediatric GIST case demographics.
Case Sex Age Location Genotype Mutation 14q32 Status SDHB IHC Follow-up Risk Histology
31 F 15 Stomach WT WT NA NA NA NA E
33 M 13 Stomach WT WT NA NA NA NA E
34 F 14 Stomach WT WT NA NA NA NA E
37 M 14 Stomach WT WT Diploid negative NA NA S&E
39 F 10 Stomach WT WT Diploid negative NA NA S&E
40 F 17 [10] Stomach WT WT Diploid negative NA NA E
41 M* 14 Stomach WT WT Diploid negative NA NA E
42 F* 17 [12] Stomach WT WT Diploid negative NA NA E
43 F 10 Stomach WT WT NA NA NA NA E
44 F* 16 Stomach WT WT NA NA NA NA E
45 F 8 Stomach WT WT NA negative NA NA E
47 M 18 Stomach WT WT NA negative NA NA E
57 M 10 Stomach WT WT NA negative NA NA E
58 F 12 Stomach WT WT NA NA NA NA NA
59 F 11 Stomach WT WT NA negative NA NA E
61 M 18 Stomach WT WT NA NA NA NA E
62 F 19 Stomach WT WT NA negative NA NA E
67 F 18 Stomach WT WT NA negative NA NA E
NA – Not Available, DOD – Died of Disease, WD – Without Disease, AWD - Alive with Disease, WT – Wild-Type, S – Spindle, E – Epithelioid, * Carney triad.
Patient demographics including age, sex, syndromic association and outcome, as well as data pertaining to tumors including anatomic location, histological type, KIT/
PDGFRA/BRAF mutational status, 14q status, risk and SDH immunoreactivity where available.
doi:10.1371/journal.pone.0064102.t003
Figure 1. Full heatmap generated from complete miRNA expression data for all 73 cases. Included at the left of heatmap are case data to
include adult/pediatric categorisation, anatomic location of tumor, KIT, PDGFRA and BRAF mutational status, risk stratification for adult mutant cases,
and, where available: Carney triad status, SDHB-immunoreactivity and 14q genomic status of tumor. Black = positive for feature listed. For age,
black = adult, grey = pediatric; for KIT/PDGFRA/BRAF black =mutation positive while grey =WT; Black =Carney triad diagnosed; for anatomic location
of tumor, grey = stomach, red = retroperitoneum, yellow= jejunum; orange = ileum; for risk, red = low, black = intermediate, green = high,
grey =unavailable. For 14q loss and SDHB status, black =positive; dark grey = tested and negative, grey = not tested. The clusters are designated
A, B, with sub-clusters B1 and B2, B2a and B2b to facilitate discussion of findings.
doi:10.1371/journal.pone.0064102.g001
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plates at a density of 26103 cells per well. Proliferation was
measured every 24 hours over a 96 hour period by reading the
plates at 495 nm, using the Synergy Mx Monochromator-Based
Multi-Mode Microplate Reader (BioTek, VT, USA).
Scratch Assay
Cells were transfected as described with miRNAs miR-34c-
5p, miR-185 and miR-190, and plated at a density of 2.46105
to allow for confluency at 48 hours. Forty-eight hours after
transfection, confluent cells were scratched with a P1000 sterile
tip, held perpendicular to the plate. Media was removed and
cells washed twice with pre-warmed PBS and once with pre-
warmed media. Fresh media was then added to the cells and
they were photographed (0 hours) using the Olympus UC30
camera attached to an Olympus CKX41SF inverted microscope
(Olympus, Tokyo, Japan). Cells were again washed at 24 and
48 hours post-scratch and photographed at these time-points
also. All images were compared to the SCR control.
Quantitative Real-Time PCR
miRNAs were extracted from the cells using the miRNeasy
miRNA mini Kit (Qiagen GmbH, Crawley, West Sussex, UK) and
quantitative Real-Time PCR was carried out as described above.
Results
Mutational Analysis
Mutational analysis showed mutually exclusive KIT mutations
in 18/73, PDGFRA in 11/73 cases and a BRAF mutation in a
single case. The remaining 43 cases were WT for the exons tested
in these genes. All clinical and genomic data are provided in
Tables 1, 2, 3.
MicroRNA Profiling
Unsupervised hierarchical clustering based on all miRNAs
showed a separation into clusters A and B (Figure 1), with cluster B
subdivided into B1 and B2. Adult mutant cases are located in
Clusters A and B1 and pediatric GISTs in Cluster B2, with adult
WT GISTs dispersed amongst both adult mutant and pediatric
WT cases (Figure 1). The clear split within the adult mutant cohort
into clusters A and B1 is due to differential expression of forty-
seven miRNAs located on chromosome 14q32.2 and 14q32.31.
Following removal of the dominant 14q miRNA cluster from the
heatmap, the split between adult mutant and pediatric WT GISTs
is accentuated with the samples split into clusters C and D, such
that adult mutant cases are in cluster C and pediatric WT cases in
cluster D (Figure 2). Both these clusters can be further subdivided
into C1, C2, D1 and D2 (Figure 2). The adult WT cases remain
dispersed amongst both adult mutant and pediatric WT cases on
this modified heatmap and the WT small bowel and retroperito-
neal GISTs cluster tightly together in Cluster C2 with adult
mutant cases (Figure 2). In both these situations, the SDHB status
underpins the clustering, such that the SDHB-immunopositive
WT gastric, small bowel and retroperitoneal cases cluster with the
adult mutant cases, while SDHB-immunonegative adult WT cases
cluster with the pediatric WT cases. Sixteen miRNAs were found
to be significantly differentially expressed between SDHB positive
and SDHB negative cases. Some of the miRNAs with recently
identified targets in vitro in various tumor settings other than GIST
include: miR-132 targeting Rb1 [32], miR-193b targeting CCND1
and Mcl-1 [33], miR-455-3p targeting Smad2 [34], miR-125b
targeting Mcl-1 and Bcl-2 [35] and miR-542-5p targeting survivin
[36]. However to-date, none of these miRNAs has been found to
target any of the subunits of SDH.
Technical Validation of miRNA Array
The miRNAs selected for validation of the TaqManH low
density array cards (Applied Biosystems, Foster City, CA, USA)
were miR-455-5p which was significantly upregulated in mutant
GIST (p,0.00003) and miRNAs miR-488 and miR-124, which
were significantly upregulated in WT GISTs (p,0.05), showing
good concordance with the array results.
Pair-wise Comparisons of miRNA Expression between
Classes of GISTs
Apart from the comparison of adult WT vs. pediatric WT, all
other paired comparisons highlighted significant differences in
miRNA expression (Table 4). Review of the putative targets of the
Figure 2. Heatmap minus dominant 14q miRNA expression. The clusters are designated C and D with sub-clusters C1, C2, D1 and D2 to
facilitate discussion of findings. Case data as delineated for figure 1. Black =positive for feature listed. For age, black = adult, grey = pediatric; for KIT/
PDGFRA/BRAF black =mutation positive while grey =WT; Black =Carney triad diagnosed; for anatomic location of tumor, grey = stomach,
red = retroperitoneum, yellow= jejunum; orange= ileum; for risk, red= low, black = intermediate, green=high, grey = unavailable. For 14q loss and
SDHB-immunoreactivity status, black = positive; dark grey = tested and negative, grey = not tested. The clusters are designated A, B, with sub-clusters
B1 and B2, B2a and B2b to facilitate discussion of findings.
doi:10.1371/journal.pone.0064102.g002
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Table 4. Significantly differentially expressed miRNAs between the various classes of GIST.
Class 1 Class 3 Class 4 Class 5 Class 6 Class 7
Adult Mutant vs.
Pediatric
Adult vs.
Pediatric
Adult WT vs.
Adult Mutant
ALL WT vs.
ALL Mutant
B2a vs. B2b SDHB+ vs. SDHB2
miRs higher in
adult mutant
miRs higher
in adult
miRs higher
in adult WT
miRs higher
in ALL WT
miRs higher
in B2b
miRs higher
in SDHB+
let-7f-2* miR-193b miR-625 miR-422a let-7d miR-132
miR-139-5p miR-455-3p miR-638 miR-423-5p let-7g miR-146a
miR-152 miR-455-5p miR-744 miR-450a let-7e* miR-193b
miR-181a-2* miR-923 miR-450b-5p miR-7-1* miR-193b*
miR-193b* miRs higher
in pediatric
miR-452 miR-17 miR-455-3p
miR-193b* miR-125b-1* miRs higher
in adult mutant
miR-488 miR-20b miR-455-5p
miR-340 miR-186 let-7f-2* miR-488* miR-26b* miR-484
miR-365 miR-488 miR-365 miR-491-5p miR-26-b-2* miR-886-5p
miR-455-3p miR-551b* miR-455-3p miR-523 miR-30b
miR-455-5p miR-576-3p miR-542-5p miR-30c miRs higher in SDHB-
miR-886-3p Class 5 miR-548b-5p miR-93* miR-125b
miR-886-5p Class 4 ALL WT vs.
ALL Mutant
miR-551b* miR-106a miR-450b
Adult WT vs.
Adult Mutant
miRs higher
in ALL WT
miR-576-3p miR-125a-5p miR-488
miRs higher in
pediatric GIST
miRs higher
in adult WT
let-7d miR-590-5p miR-126 miR-488*
miR-7-2* miR-16 miR-16 miR-625 miR-132 miR-542-3p
miR-15a miR-20b miR-20b miR-638 miR-191 miR-551b
miR-16 miR-28-3p miR-28-3p miR-873 miR-212 miR-576-3p
miR-34c-5p miR-34c-5p miR-34c-5p miR-923 miR-331-3p miR-769-5p
miR-125a-3p miR-124 miR-124 miR-339-3p
miR-125b-1* miR-125a-3p miR-125a-3p miR-340*
miR-126 miR-126* miR-125b-1* Class 5 miR-342-3p Class 8
miR-129-3p miR-126 miR-126 miRs higher
in ALL Mutant
miR-361-5p 14q Loss vs.
No Loss
miR-186 miR-129.3p miR-126* miR-let-7f-2* miR-362-3p miRs higher with no 14q
Loss
miR-190 miR-129.5p miR-129-3p miR-152 miR-363 miR-20b
miR-192 miR-155 miR-129-5p miR-154 miR-374a
miR-210 miR-181a-2* miR-155 miR-193b miR-374b
miR-214 miR-185 miR-181a-2* miR-193b* miR-484
miR-345 miR-186 miR-184 miR-302b miR-532-3p
miR-361-5p miR-197 miR-185 miR-324-5p miR-598
miR-383 miR-202 miR-186 miR-365 miR-671-3p Class 9
miR-422a miR-210 miR-192 miR-377* miR-708 High vs. Low Risk
miR-423-5p miR-214 miR-197 miR-410 miR-744* miRs higher in low risk
miR-450a miR-331-5p miR-202 miR-455-3p miR-150
miR-450b-5p miR-339-3p miR-210 miR-455-5p miRs higher in B2a
miR-488* miR-345 miR-214 miR-668 miR-572
miR-488 miR-361-5p miR-331-5p miR-744 Class 10
miR-491-5p miR-422a miR-338-3p DOD/AWD vs. NED
miR-523 miR-450a miR-339-3p miRs higher in DOD/
AWD
miR-542-5p miR-452 miR-340 miR-19b
miR-551b* miR-523 miR-342-3p
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miRNAs, using TargetScan [18–20], showed that many are
predicted to target genes of known biological importance in GIST,
including KIT, PDGFRA, IGF1R and MAPK1.
Bioinformatic Evaluation of miRNA: mRNA Interactions
The data were interrogated for likely significant biological
interactions between diametrically expressed miRNA and mRNA
as described above. To determine if any miRNAs were predicted
to target these inversely expressed mRNAs we used the
TargetScan database of predicted interactions [18–20]. In the
comparison of significantly up-regulated mRNAs: down-regulated
miRNAs in the pediatric versus adult mutant classes, we observed a
significantly (p,0.006) higher degree of predicted interactions
than expected. These bioinformatic data suggest that the
differential expression of these mRNAs may be due in some part
to post-transcriptional regulation by these differentially expressed
miRNAs. These interactions included ANK3, IGF1R, NLGN4X,
FZD2 and PHKA1 with miR-139-5p, miR-152, miR-193b, miR-
340 miR-365, 455-5p, 455-3p, 886-3p and 886-5p. From the full
raw gene expression dataset [5], only for the comparison where
gene expression was higher and miRNAs lower in mutant versus
WT GIST, were the predicted mRNA: miRNA interactions
significantly (p,0.0121) over-represented, suggesting that these
interactions might be functionally relevant. These included
interactions of miR-509-5p, 330-3p, 455-5p, 152, 193b, 302b
and 365 with IGF1R, PPARGC1A and PRDM16.
Fluorescence In-Situ Hybridisation (FISH)
FISH analysis for 14q32 was performed on 28 adult mutant
samples, with 82% of cases showing 14q32 loss. FISH analysis for
14q32 in 2 adult WT samples and 5 pediatric samples all showed a
diploid phenotype at 14q32 (Tables 1, 2, 3).
Methylation Analysis of 14q32 Region
While 14q loss is a common genomic observation with disease
progression in adult mutant GIST, it is immediately obvious from
the heatmap annotations, that there is no direct correlation
between 14q miRNA expression and 14q genomic status (in cases
where it was possible to investigate 14q loss by FISH). Eighty-two
percent of adult mutant cases tested show 14q32 loss (Table 1).
This is a known imprinted region on 14q32 and all miRNAs in this
region are derived from one transcript which is maternally
expressed [37,38]. We hypothesised that differential allelic losses in
this imprinted region might explain the observed miRNA
expression patterns. In other words, loss of 14q32 involving the
paternal allele would effectively be silent and so, despite evidence
of genomic loss by FISH, the maternal expressed allele would be
retained, explaining expression of the miRNAs on the heatmap for
such cases. We tested this by examining the methylation status of
the 14q region. Preferential loss of the paternal [silent] allele was
observed in 75% [9/12, of which 2= adult WT] of cases tested
from Cluster A, where there is relative preservation of 14q miRNA
expression (Figure 3), while the expressing maternal allele is
preferentially lost in 83% [5/6, of which 2= adult WT] of cases
tested from Clusters B1 (Figure 4). Importantly, the remaining
cases tested from clusters A and B1 all showed normal methylation
patterns. The pediatric cases tested show normal methylation
patterns in conjunction with an absence of genomic losses of the
14q region, such that their relatively lower expression of 14q
miRNAs in this cohort must be accounted for by some other
mechanism.
From the full heatmap (Figure 1) Cluster B2 can be further
subdivided into Cluster B2a and B2b. Note that all known Carney
triad patients (n = 4) fall into Cluster B2b.
Table 4. Cont.
Class 1 Class 3 Class 4 Class 5 Class 6 Class 7
miR-576-3p miR-542-5p miR-345
miR-590-5p miR-548b-5p miR-361-5p
miR-744 miR-548c-3p miR-363
miR-873 miR-548d-5p miR-383
The various pair-wise comparisons between classes of GIST are listed with miRNAs significantly differentially expressed between these.
doi:10.1371/journal.pone.0064102.t004
Figure 3. Loss of Paternal 14q32 Allele in Cluster A. Agarose gel for cases in Cluster A showing loss of the paternal allele. Lane 1: Molecular
marker, 2: NTC-no template control, 3: Normal sample, 4: Normal sample unconverted, 5: positive maternal UPD14, Lanes 6–8: adult mutant cases.
doi:10.1371/journal.pone.0064102.g003
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SDHB Immunohistochemistry
SDHB immunohistochemistry was performed on 32/73 sam-
ples for which slides were available. Eleven adult WT and 11
pediatric WT cases were negative for SDHB and 7 adult WT and
3 adult mutant cases were positive for SDHB (Tables 1, 2, 3).
Cell Proliferation and Scratch Assay
Transfection of GIST T1 cells with mature miRNA mimics
miR-34c-5p, miR-190 and miR-185, all of which are expressed at
higher levels in pediatric (34c-5p and 185 also in adult WT)
compared with adult mutant cases, showed a decrease in wound
healing compared to the scrambled control (Figure 5A–H). While
miR-34c-5p, miR-185 and miR-190 furthermore demonstrated
significantly (P,0.001) decreased cell proliferation compared the
scrambled control (Figure 5I–K).
Discussion
Prompted by the lack of data from genomic studies to explain
pediatric/WT GIST oncogenesis, we undertook this study of
miRNA profiling to investigate a role for post-transcriptional
dysregulation by these non-coding RNAs in pediatric/WT GIST
development. Unsupervised hierarchical clustering split the cases
into two large groups, Cluster A and Cluster B, resulting from
differential expression of forty-seven miRNAs located on 14q32.2
and 32.31. Two prior studies [39,40] showed similar differential
miRNA expression patterns in adult mutant GIST based on 14q
status, as well as other clinico-pathological variables. However
neither of those studies addressed the methylation status of the
retained 14q allele in their cases showing 14q loss. We found no
direct relationship between 14q genomic status and 14q32 miRNA
expression in this cohort. Eighty-two percent of adult mutant cases
tested showed 14q loss, yet many of these in fact show relatively
higher 14q miRNA expression than cases with the normal (diploid)
FISH result as seen in all pediatric cases. The 14q32 region is a
known imprinted region in both mice (where the corresponding
region is located on distal chromosome 12) and humans
[37,38,41], containing maternally- and paternally-expressed genes.
The miRNAs located within this cluster all map within a 40 kb
interval and are controlled by a differentially methylated region
(IG-DMR) 200 kb away [37,38,42]. miRNAs in this region are
only expressed from the maternal allele [37,38], as the paternal
allele is silenced by methylation, and these miRNAs are thought to
be transcribed as a large single poly-cistronic cluster (precursor
transcript) rather than as individual primary transcripts [37].
Therefore, deletion of the active maternal allele is required for
complete loss of expression of these miRNAs. We hypothesised
that the adult mutant cases showing 14q loss with relatively higher
14q miRNA expression (Cluster A) must retain the active maternal
allele, while the cases with lower 14q miRNA expression (Cluster
B) retain the silent paternal allele, resulting in down-regulation of
these miRNAs. To investigate this, we applied the diagnostic assay
used for the detection of uniparental disomy (UPD) for chromo-
some 14q [30]. UPD is the inheritance of both homologues of a
chromosome from one parent [43]. 14q32 contains the respec-
tively maternally- and paternally- expressed MEG3 and DLK1
genes, which contribute to different phenotypes in maternal and
paternal UPD14 [30,41,43] and are regulated by a differentially
methylated region (DMR) that extends over the MEG3 promoter.
This is the IG-DMR referred to above which controls the miRNA
cluster. The assessment for UPD14 relies on a methylation-specific
multiplex PCR to amplify methylated and unmethylated elements
of the DMR and identify normal pattern methylation, maternal or
paternal UPD14 [30]. Our results suggest that the adult cases do
fit our hypothesis, with 75% (9/12) of cases that were tested from
Cluster A showing convincing loss of the paternal allele (Figure 3),
while the remaining 3 cases showed a normal pattern; and 83%
(5/6) of cases tested from Cluster B1 showing loss of the maternal
allele (Figure 4) with the last case showing a normal pattern of
methylation. We explain the lack of a perfect correlation between
the methylation status of the 14q region and miRNA expression by
likely admixture of DNA from non-tumor tissue elements retaining
the normally imprinted arrangement. Our hypothesis does not
hold true for the pediatric WT cases, with the majority of cases
tested showing normal methylation patterns, suggesting that some
other mechanism must underlie the down-regulation of the
miRNAs in this region in this setting. Further investigation is
required to elucidate this.
Many miRNAs are categorised into clusters, often located at
fragile sites [44]. The forty-seven miRNAs located on 14q32
represent one of the largest clusters identified to-date [45] and
have been found down-regulated or silenced in many cancers
including gliomas [45] and epithelial ovarian cancers [46],
suggesting a possible tumor suppressor role for the miRNAs
located in this cluster. Few of the 14q32 miRNAs have been
studied in vitro with target validation. Of those differentially
expressed in our study, 14q32 miRNAs having confirmed targets
include miR-127 (located within a CpG island and silenced in
many cancers) targeting BCL-6 [47], miR-154 targeting CCND2
[48], miR-433 targeting HDAC6 [49], miR-485-3p targeting NF-
YB [50] and miR-539 targeting HLCS [51]. Using target
Figure 4. Loss of Maternal 14q32 Allele in Cluster B1. Agarose gel for cases in Cluster B1 showing loss of the maternal allele. Lane 1: Molecular
marker, 2: NTC-no template control, 3: Normal sample, 4: Normal unconverted, 5: positive maternal UPD14, 6–7: adult mutant cases.
doi:10.1371/journal.pone.0064102.g004
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prediction algorithms, including TargetScan, [18–20], it emerges
that these miRNAs may target genes of known importance in
GIST cell biology including KIT, PDGFRA IGF1R, NF1, MAPK1,
SDH and KRAS [9,14,28], however further investigation is
required to confirm this as well as other potentially important
gene targets. Recently miR-494 was shown to target KIT in the
GIST882 cell line [52]. Up-regulation of miR-494 in GIST882
cells reduced the expression of KIT and its downstream signalling,
increased apoptosis and inhibited cell growth, suggesting the
possible importance of loss of miR-494 and perhaps indeed all 47
miRNAs on 14q32 in GIST progression [52].
On the heatmaps (Figures 1; 2), the pediatric cases consistently
cluster separately from the adult mutant cases. As described, our
functional assays suggest that the differentially expressed miRNAs
producing this clustering indeed have biological effects on GIST
cell lines. The miRNAs chosen here have proven targets in other
neoplasms. miR-34c-5p targets E2F3, MYCN, Bcl-2 and c-Met
[53,54], while miR-185 targets RhoA and Cdc42 [55]. Ectopic
expression of miR-34c-5p in cervical cancer cells inhibited
proliferation and anchorage independent growth, while ectopic
expression of miR-185 in colorectal cancer cells also inhibited
proliferation, induced G1 cell cycle arrest and apoptosis, and
Figure 5. Functional studies of selected differentially expressed miRNAs. Transfection with miR-34c-5p, miR-190 and miR-185, (all of which
are expressed at higher levels in pediatric compared with adult mutant cases), show decreased wound healing compared to the SCR control 48 hours
after scratch assay (Figures A–H). Ectopic expression of miR-34c-5p, miR-190 and miR-185 showed a significant decrease in cell proliferation at 96
hours, as measured using an MTS assay, compared to the SCR control (Figures I–K). KIN = siKinesin (positive control for reduced cell proliferation),
SCR= scrambled oligonucleotide control, NTC= non-transfected control.
doi:10.1371/journal.pone.0064102.g005
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blocked invasion, suggesting tumor suppressive roles for both these
miRNAs [53–55]. Their lower expression in adult mutant GISTs
might contribute to the more aggressive course of these tumors
compared with their WT counterparts where expression is higher.
Cluster B2 consists of all pediatric and sixteen adult WT gastric
cases which can be further split into Clusters B2a and B2b. All
known Carney triad cases cluster together in B2b, which could
also contain cases not yet definitively diagnosed as Carney triad at
the time of writing (n = 4). In the dyad, paraganglioma is typically
the first tumor manifestation, with GIST following, however in
Carney triad, generally GIST is the first tumor diagnosed and it
can take many years for other tumors [pulmonary chondroma and
paraganglioma] to develop, so that the diagnosis of Carney triad
may be delayed by years or even decades. The miRNAs
differentially expressed between Clusters B2a and B2b therefore
may represent a signature that could prompt closer patient
monitoring for development of additional tumor manifestations of
Carney triad compared to those patients in Cluster B2a. A larger
cohort with retrospective clinical data is required for confirmation
of such a theory. Thirty-four miRNAs are differentially expressed
between the Clusters B2a and B2b. Some of these, including let-
7g, miR-212 and miR-132 are known to target c-MYC [56], Rb1
[32] and RASA1 [57] respectively, in various other tumors.
The heatmap following removal of the dominant 14q cluster
(Figure 2) still clearly shows that the adult WT cases are dispersed
between adult mutant and pediatric cases and this is apparently on
the basis of SDHB reactivity. It has emerged recently that SDHB
immunoreactivity is tightly correlated with mutational status in
GIST such that mutant cases are consistently SDHB-immunopo-
sitive while WT cases are frequently SDHB-immunonegative,
notably in the pediatric setting [13,14]. A result which parallels
ours, has recently been identified by Killian et al [58] showing that
WT GISTs demonstrating a ‘‘methyl centrist’’ profile (a methyl-
ation pattern which resembles that of normal tissues) were all
positive for SDHB immunohistochemically and had clinical
characteristics similar to mutant GISTs with greater tyrosine
kinase inhibitor response, while WT GISTs within the ‘‘methyl
divergent’’ group (cases showing an outlier methylation pattern
relative to normal tissues and mutant GIST samples) were all
negative for SDHB by immunohistochemistry and behaved
clinically similarly to pediatric GISTs. Both of these epigenetic
studies –the Killian et al methylation data and our miRNA
profiling -have therefore separated adult WT GISTs based on
their SDHB immunohistochemistry status, placing SDHB-immu-
nopositive WT GISTs with adult mutant GISTs, a finding which
raises the tantalising possibility that these tumors bear yet-to-be
identified oncogenic kinase mutations. Such a pattern is observed
not only for gastric adult WT GISTs, but particularly also for those
cases arising in small bowel and retroperitoneum in our cohort.
The more meaningful categorisation of GIST emerging on
multiple levels at this stage then, is one based on SDHB
immunoreactivity, with the implication that oncogenesis is driven
by impaired cellular respiration in the SDHB-immunonegative
cases [13,14,59].
In summary then, this study has shown very discrete clustering
of subsets of GIST based on miRNA profiles with evidence of
some functional effects of these differentially expressed miRNAs,
excellent clinico-pathological correlations and implications for
post-transcriptional dysregulation in pediatric/WT GIST onco-
genesis.
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